PTGX

Protagonist Therapeutics
PTGX

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$2.83B
EV
$2.29B
Shares Outstanding
65.95M
Beta
2.29

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$69.10
P/E 2025E
-
P/Revenue 2025E
28.68x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Protagonist Therapeutics, Inc.

gainify
PTGX

Protagonist Therapeutics, Inc.

PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 c...

Sector

Healthcare

Industry

Biotechnology

CEO

Patel, Dinesh

Employees

126

IPO Date

2016-08-11

Headquarters

7707 Gateway Boulevard, Suite 140, Newark, California, 94560-1160, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved